NCT06764862View on ClinicalTrials.gov

Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary Fibrosis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 27, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

July 15, 2026

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

HSK44459 dose 1

HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.

DRUG

HSK44459 dose 2

HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.

DRUG

Placebo

Placebo matching HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY